Knowledge, Attitude and Practice of the use of Nanoparticles in the Treatment
of Oral Cancer Patients

Diksha      Mohapatra; Neeta      Mohanty; Shakti      Rath

doi:10.2174/03666220921100058

Abstract

Aims: To determine the knowledge, attitude and practice of the use of nanoparticles amongst health care professionals for treating oral cancer patients. Also, to understand the indications and contraindications of nanoparticles in treating oral cancer patients.

Methods: A descriptive cross-sectional study was executed amongst dental surgeons practising with undergraduate and post-graduate degrees. A Google questionnaire form was developed and distributed, and 102 authentic entries were short-listed. Data obtained from the study were recorded in Microsoft Excel 2007 version, and SPSS version 18.0 was used. Calculation of statistical analysis like mean and standard deviation and analysis between variations was done using student t-tests, and the association between variables was determined using Chi-square. A value was found significant when the p-value was less than 0.05.

Results: Many practitioners have been using nanoparticles prepared by using nanobiotechnology for the last 2-4 years. About 92.9% of participants were well conversant with nanoparticles in treating oral cancer patients, out of which 88% are willing to specify therapeutic medicaments prepared using nano-biotechnology for oral cancer patients. About 94.9% of the dentists accepted the fact that nanomedicine can also be used in combination therapy for treating patients, and 98% stated that the use of nanotechnology for diagnosing as well as treating patients will not only be advantageous but will also be the new face of cancer management shortly.

Conclusion: Lack of awareness, increased tobacco consumption, and late diagnosis are the prime concerns regarding increased oral cancer cases and decreased prognosis. Nanoparticles having a small particulate size will be able to detect the changes on the surface and the cellular levels and inside the cells. Similarly, in the case of therapeutic use, nanoparticles are highly efficient in delivering drugs to systemic circulation by reducing the drug’s immunogenicity by releasing the drug in an environmentally responsive dose, thus lowering the frequency of administration and systemic toxicity.

Keywords: Nanoparticles, Nanotechnology, Nanomaterials, Oral Cancer, Chemotherapy, Radiation therapy

[1]
Biswas P, Wu CY. Nanoparticles and the environment. J Air Waste Manag Assoc  2005; 55(6): 708-46.
 [http://dx.doi.org/10.1080/10473289.2005.10464656] [PMID: 16022411]

[2]
Wang S, Zhang Y, Qin X, et al. Guanosine assembly enabled gold nanorods with dual thermo- and photoswitchable plasmonic chiroptical activity. ACS Nano  2020; 14(5): 6087-96.
 [http://dx.doi.org/10.1021/acsnano.0c01819] [PMID: 32374982]

[3]
Aghebati-Maleki A, Dolati S, Ahmadi M, et al. Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol  2020; 235(3): 1962-72.
 [http://dx.doi.org/10.1002/jcp.29126] [PMID: 31441032]

[4]
Ribeiro ACP, Silva ARS, Simonato LE, Salzedas LMP, Sundefeld MLMM, Soubhia AMP. Clinical and histopathological analysis of oral squamous cell carcinoma in young people. Br J Oral Maxillofac Surg  2009; 47(2): 95-8.
 [http://dx.doi.org/10.1016/j.bjoms.2008.05.004] [PMID: 18586366]

[5]
Pei W, Li X, Bi R, et al. Exosome membrane-modified M2 macrophages targeted nanomedicine: Treatment for allergic asthma. J Control Release  2021; 338: 253-67.
 [http://dx.doi.org/10.1016/j.jconrel.2021.08.024] [PMID: 34418524]

[6]
Wang K, Feng Y, Li S, et al. Oral delivery of bavachinin-loaded PEG-PLGA nanoparticles for asthma treatment in a murine model. J Biomed Nanotechnol  2018; 14(10): 1806-15.
 [http://dx.doi.org/10.1166/jbn.2018.2618] [PMID: 30041726]

[7]
Zhang L, Chan J, Wang A, Langer R, Farokhzad O. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther  2008; 83(5): 761-9.

[8]
Zhang Y, Li M, Gao X, Chen Y, Liu T. Nanotechnology in cancer diagnosis: Progress, challenges and opportunities. J Hematol Oncol  2019; 12(1): 137.
 [http://dx.doi.org/10.1186/s13045-019-0833-3] [PMID: 31847897]

[9]
Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano  2009; 3(1): 16-20.
 [http://dx.doi.org/10.1021/nn900002m] [PMID: 19206243]

[10]
Rai M, Ingle AP, Birla S, Yadav A, Santos CAD. Strategic role of selected noble metal nanoparticles in medicine. Crit Rev Microbiol  2016; 42(5): 696-719.
 [PMID: 26089024]

[11]
Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res  2010; 62(2): 90-9.
 [http://dx.doi.org/10.1016/j.phrs.2010.03.005] [PMID: 20380880]

[12]
Stephen BJ, Suchanti S, Mishra R, Singh A. Cancer nanotechnology in medicine: A promising approach for cancer detection and diagnosis. Crit Rev Ther Drug Carrier Syst  2020; 37(4): 375-405.
 [http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2020032634] [PMID: 32865930]

[13]
Chen T, Ren L, Liu X, et al. DNA nanotechnology for cancer diagnosis and therapy. Int J Mol Sci  2018; 19(6): 1671.
 [http://dx.doi.org/10.3390/ijms19061671] [PMID: 29874867]

[14]
Surendiran A, Sandhiya S, Pradhan SC, Adithan C. Novel applications of nanotechnology in medicine. Indian J Med Res  2009; 130(6): 689-701.
 [PMID: 20090129]

[15]
Shashirekha G, Jena A, Mohapatra S. Nanotechnology in dentistry: Clinical applications, benefits, and hazards. Compend Contin Educ Dent Jamesburg NJ 1995  2017; 38(5): e1-4.

[16]
Zanoni DK, Montero PH, Migliacci JC, et al. Survival outcomes after treatment of cancer of the oral cavity (1985–2015). Oral Oncol  2019; 90: 115-21.
 [http://dx.doi.org/10.1016/j.oraloncology.2019.02.001] [PMID: 30846169]

[17]
Lee H, Shields AF, Siegel BA, et al. 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin Cancer Res  2017; 23(15): 4190-202.
 [http://dx.doi.org/10.1158/1078-0432.CCR-16-3193] [PMID: 28298546]

[18]
Mokhtari RB, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget  2017; 8(23): 38022-43.
 [http://dx.doi.org/10.18632/oncotarget.16723] [PMID: 28410237]

[19]
Hoffmann C, Calugaru V, Borcoman E, et al. Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. Eur J Cancer Oxf  Engl 1990  2021; 146: 135-44.

[20]
de Jong WH, Borm PJ. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine  2008; 3(2): 133-49.
 [http://dx.doi.org/10.2147/IJN.S596] [PMID: 18686775]